Skip to main content
PCVX
NASDAQ Life Sciences

Vaxcyte Completes Enrollment for All VAX-31 Phase 3 Trials, Reports Strong Q1 Cash Position

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$57.1
Mkt Cap
$8.245B
52W Low
$28.09
52W High
$65
52W Position info
103% above low
Off High info
12% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

PCVX has more than doubled off its 52-week low of $28.09.

Summary

Vaxcyte announced the completion of enrollment for all VAX-31 adult Phase 3 and infant Phase 2 trials, alongside a strong cash position of $2.7 billion following a $601.8 million equity offering.


Key Events · Product Development and Regulatory · PCVX

  • VAX-31 Phase 3 Adult Trials Fully Enrolled

    Enrollment is now complete for the OPUS-1, OPUS-2, and OPUS-3 Phase 3 trials evaluating VAX-31 for invasive pneumococcal disease and pneumonia in adults. Topline data for OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results in H1 2027.

  • VAX-31 Infant Phase 2 Study Enrollment Completed

    The VAX-31 infant Phase 2 dose-finding study has completed enrollment, with topline data from the primary immunization series and booster dose expected by the end of H1 2027.

  • Strong Cash Position Maintained

    Cash, cash equivalents, and investments totaled approximately $2.7 billion as of March 31, 2026, including $601.8 million in net proceeds from a February 2026 equity offering, providing a substantial runway for pipeline development.

  • VAX-A1 Phase 1 Study Initiation Planned

    The company expects to initiate a Phase 1 adult clinical study for VAX-A1, a vaccine candidate to prevent disease caused by Group A Strep, in mid-2026.


Analysis · PCVX · Life Sciences

Vaxcyte, a clinical-stage vaccine company, announced significant progress in its lead VAX-31 vaccine program, completing enrollment for all three adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) and the infant Phase 2 study. These milestones are critical for advancing VAX-31 towards potential regulatory submission and commercialization. The company also reported a robust cash position of approximately $2.7 billion, bolstered by the successful completion of a $601.8 million net proceeds equity offering in February 2026. While the net loss widened due to increased R&D expenses, this reflects the accelerated development of its pipeline, including plans to initiate a Phase 1 study for VAX-A1 in mid-2026. The strong financial runway and consistent execution on clinical timelines de-risk the company's development path.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCVX was trading at $57.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $28.09 to $65.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCVX - Latest Insights

PCVX
Nov 04, 2026, 5:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $65.68
Real-time Price: $55.30 info
Change: -$10.38 (-16%) info
Market Cap: $8.82B info
PCVX
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $65.68
Real-time Price: $55.30 info
Change: -$10.38 (-16%) info
Market Cap: $8.82B info
PCVX
Oct 09, 2026, 4:42 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.12
Real-time Price: $55.30 info
Change: -$15.82 (-22%) info
Market Cap: $8.82B info
PCVX
Oct 08, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $64.94
Real-time Price: $55.30 info
Change: -$9.64 (-15%) info
Market Cap: $8.82B info
PCVX
Oct 07, 2026, 6:05 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $66.40
Real-time Price: $55.30 info
Change: -$11.10 (-17%) info
Market Cap: $8.82B info